

# RECORDING NOTICE

ATTENTION: This meeting will be recorded. Pursuant to UPMC Policy No. HS-IS0241, no Confidential Information may be discussed during the meeting.

Confidential Information includes: Protected Health Information; information about specific UPMC patients (de-identified or not), specific UPMC employees (de-identified or not) or specific UPMC Health Plan members (de-identified or not); UPMC's proprietary business information; privileged communications between UPMC counsel and UPMC personnel; and information subject to a UPMC legal or contractual obligation.

If you choose to attend this meeting, you consent under the governing law to the recording.

You will have no obligation to appear, speak, or participate in the meeting. You may mute your microphone and turn off your camera for the entirety of the meeting.



## Oh Oh Oh So Many Uses! GLP-1 Receptor Agonists in Special Populations: Dumping Syndrome, Depression, and Retinopathy

Leah Korte, PharmD

PGY2 Pharmacy Resident, Ambulatory Care

UPMC Presbyterian Shadyside

# Continuing Education Information

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Pharmacy (CPE)

This knowledge-based activity provides **1.0 contact hours** of continuing pharmacy education credit

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

# Disclosures

No members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity of producing, marketing, re-selling, or distributing health goods or services, used on, or consumed by patients to disclose.

# Disclaimer

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

# Learning Objectives

1. Describe the mechanism of action of glucagon-like peptide-1 receptor agonists (GLP1RAs) as it relates to dumping syndrome, depression, and diabetic retinopathy.
2. Recognize the risks versus benefits of GLP1RA use in dumping syndrome, depression, and diabetic retinopathy.
3. Discuss GLP1RAs' place in therapy for the treatment of dumping syndrome, depression, and diabetic retinopathy.